Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of invasive interventional therapies for structural heart diseases in the People's Republic of China. The company offers LuX-Valve, a transcatheter tricuspid valve replacement (TTVR) product candidate for the treatment of severe tricuspid regurgitation and high surgical risk; and Ken-Valve, a transcatheter aortic valve replacement product candidate for the treatment of severe aortic regurgitation or combined with aortic stenosis. Its products have applications in the treatment of structural heart diseases, including tricuspid valve diseases, aortic valve diseases, mitral valve diseases, and heart failure. The company was incorporated in 2011 and is headquartered in Ningbo, the People's Republic of China.
Stock data | 2024 | Change |
---|---|---|
Price | $0.4272789281991222 | N/A |
Market Cap | $56.23M | N/A |
Shares Outstanding | 131.59M | N/A |
Employees | 337.00 | N/A |